PLA2R1 and membranous glomerulonephritis: We designed this randomized controlled study to investigate whether a personalized treatment approach based on the rituximab regimen tailored to the epitope spreading status of the patient (marker-based strategy design)31 is superior to the standard GEMRITUX protocol in achieving remission at month-12 for patients with PLA2R1-associated membranous nephropathy.